Myeloma
-
CAR T-cell Therapy: Understanding the Warning and the RisksThe FDA requires a warning with CAR T-cell therapies about an increased risk of cancer from the treatment. Should you be concerned?
by Sandra Gordon
-
Real-world Outcomes in Multiple MyelomaStudy shines a light on the differences in outcomes between clinical trial patients with multiple myeloma and those receiving cancer treatment in their community.
by Sandra Gordon
-
Living With Chronic Blood CancerThanks to medical advances, more people with blood cancer are living for years or even decades after their diagnosis. But when these diseases are incurable, patients must learn to adjust to ongoing monitoring and treatment.
by Kendall K. Morgan
-
Forward Look
Bispecific Antibodies to Treat CancerHematologist-oncologist Saad Usmani talks about recent approvals for bispecific antibodies to treat multiple myeloma and other blood cancers.
by Ashley P. Taylor
-
Taking Stock of CAR T-Cell TherapyFive years after the FDA approved the first CAR T-cell therapy, use of the treatment has expanded to many patients with blood cancer.
by Kendall K. Morgan
-
The View From a CAR T-Cell Clinical TrialAfter exhausting her treatment options, Ellen Reich got CAR T-cell treatment for multiple myeloma through a clinical trial.
by Pamela Rafalow Grossman
-
Forward Look
Crowdsourcing SupportAfter struggling to understand her treatment options for multiple myeloma, Jenny Ahlstrom started a virtual platform for patients to gather information about blood cancers.
by Allison Futterman
-
Forward Look
First CAR-T Cell Therapy Approved for Multiple MyelomaCellular immunotherapies can offer periods when people do not require treatment.
by Christina Bennett
-
More Data on COVID-19 Vaccination and CancerStudies indicate that many people with cancer have an antibody response to the vaccines, but this response may be reduced or absent in certain patients.
by Anna Goshua
-
Searching the Blood for Signs of Altered ImmunityThe immune systems of people with blood cancer respond differently to infection with the coronavirus than the immune systems of people without cancer or with solid tumors.
by Kate Yandell
